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Activated protein C resistance: Prevalence 
and implications in peripheral vascular disease 
Kenneth Ouriel, MD, Richard M. Green, MD,  James A. DeWeese, MD,  and 
Cathy Cimino, BA, Rochester, N.Y. 
Purpose: Activated protein C (APC) is a naturally occurring anticoagulant that interacts 
with factors V and VIII to inhibit the clotting cascade. Resistance to APC (APC-R), 
hypothesized to occur as a result of an abnormal factor V, has been documented in up to 
40% of patients with venous thrombotic events, but its prevalence in patients with arterial 
disease remains ill defined. 
Methods: With an assay of APC resistance that expresses the ratio of the activated partial 
thromboplastin time with and without he addition of exogenous APC, APC resistance 
ratios were quantitated in 200 individuals comprising 177 patients with vascular disease 
and 23 control subjects. An abnormal activated partial thromboplastin time was present 
in four patients who were excluded from analysis. The 173 remaining patients formed the 
study population and were divided into diagnostic subgroups on the basis of the most 
symptomatic problem. 
Results: APC resistance was documented in 20 individuals, representing 11.6% of the 
study group. The highest prevalence ofAPC resistance was observed in patients with lower 
extremity occlusive disease, with the APC-R ratio below 2.0 in 13.7%. Within the 
subgroup of individuals with lower extremity disease, 76 patients (10 with APC-R, 
13.2%) underwent infrainguinal bypass and were monitored amean of 47 + 8 months. 
Occlusion of the arterial reconstruction ccurred in 22 patients (29~ Six (60%) of the 
patients with APC-R had failed reconstructions, versus 16 (24%) of 66 patients without 
APC-R (p = 0.02). 
Conclusions: These findings suggest hat APC-R is relatively common in patients with 
peripheral vascular disease, especially in those with lower extremity occlusive disease. 
APC-R appears to be a risk factor for failure of infrainguinal bypass. These observations 
suggest hat screening for APC-R may be useful in patients with peripheral vascular 
disease, providing the opportunity to restore the normal thrombogenic balance with 
anticoagulant therapy in susceptible individuals. (J VASC SURG 1996;23:46-52.) 
Protein C is a vitamin K-dependent plasma pro- 
tein that, when activated, functions as a naturally 
occurring anticoagulant to limit ongoing thrombo- 
genesis. 13 A hereditary disorder in the protein C 
pathway has been described, constituting an impor- 
tant risk factor for venous thrombocmbolic disease. 4 
These individuals have normal evels of protein C but 
manifest an abnormally low anticoagulant response 
to the addition of exogenous activated protein C 
(APC). 5~6 Recently a mutation in the factor V gene 
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has been identified as the etiologic mechanism 
whereby the structurally abnormal factor V protein is 
not susceptible to inactivation by APC. 7'8 
The incidence of APC resistance has been found 
to range as high as 20% to 40% in patients with 
venous disease, 6 9 but the frequency of APC resis- 
tance in patients with peripheral arterial disease has 
not been well defined. The implications of  APC 
resistance are unknown in the group of individuals 
undergoing peripheral vascular surgery, specifically 
with regard to the risk of postoperative thrombotic 
events. This study was undertaken to document the 
prevalence of APC resistance in patients with periph- 
eral vascular disease, correlating the disorder with 
outcome after vascular surgery. 
PAT IENTS AND METHODS 
The study group comprised 177 patients with 
peripheral vascular disease admitted on an outpatient 
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basis over the 2-month period between September 
and November 1994. These patients were compared 
with a control group of 23 volunteers without a 
history of arterial or venous thrombotic disease. 
Patients were subgrouped with respect to major 
diagnostic ategories, including carotid artery dis- 
ease, aortic aneurysm, lower extremity occlusive 
disease, and venous thrombotic disease. Vascular 
disease was present in two or more systems in 20 
patients who were included within multiple sub- 
groups for descriptive purposes. Statistical analyses, 
however, were performed with each patient in a 
single subgroup corresponding to the most severe 
clinical manifestations. 
Assay for APC resistance. APC resistance was 
tested by measuring the response in the activated 
partial thromboplastin time (aPTT) to exogenously 
administered APC. Blood (9 ml) was drawn into 
plastic syringes and mixed with 1 ml sodium citrate 
(0.1 mol/L). The anticoagulated specimens were 
centrifuged for 20 minutes at 2000g. The plasma was 
then separated from the cellular layers and 1 ml 
aliquots were rapidly frozen at - 70 ~ C. Subsequent 
analysis was begun by thawing the specimens at 37 ~ 
C and adding 1 ml purified phospholipid and 
colloidal silica (aPTr reagent). The mixture was 
incubated for 5 minutes at 37 ~ C, and 1 ml CaCI 2 
(0.025 mol/L) was then added; clot formation was 
timed by use of an automated method. A second 
analysis was performed, with addition of 1 ml human 
APC colyophilized with CaCI 2 and reconstituted 
with 2 ml sterile water. The APC resistance ratio 
(APC-RR) was calculated as follows: 
Time to clot formation with APC/CaCI 2 
Time to clot formation with CaCI 2 alone 
Specimens were tested in duplicate when the 
APC-RR was below 2.0. Patients with APC-RR 
below 2.0 underwent phlebotomy to assay the levels 
of proteins C and S, antithrombin III, and anti- 
cardiolipin antibody. Patients with abnormally 
prolonged aPTT (greater than 42 seconds) caused 
by deficiencies in intrinsic coagulation factors or 
the presence of circulating anticoagulants were ex- 
cluded from data analysis, as were patients receiving 
oral anticoagulants and patients with renal insuf- 
ficiency. 
Statistical methods. Continuous variables were 
expressed as mean +_ the standard error of the mean 
and compared by use of the Student t test. Dichoto- 
mous variables were assessed through calculation of 
Pearson's correlation coefficient. Censored ata were 
analyzed with Kaplan-Meier analysis, ~~ with the 
Peto-Prentice statistic used for comparisons between 
subgroups. ~ Significance was assumed when the 
two-tailedp value was less than 0.05. 
RESULTS 
The APC-RR in the 23 control subjects ranged 
from 2.12 to 2.84, with a mean of 2.40 + 0.04. With 
a 95% confidence interval to define the range of 
normal, the lower limit of normal APC-RR was 2.0. 
An elevated baseline aPTT was present in four 
patients who were excluded from subsequent data 
analysis. The APC-RR averaged 2.26 _+ 0.02 in the 
173 remaining patients and was below the range 
considered normal in 20 (11.6%) individuals (Table 
I). There were no differences in the male/female ratio 
in the patients with and without APC resistance, 
averaging approximately 2:1. In patients with arterial 
disease, the age at onset of the thrombotic problem 
was greater in patients with APC resistance, 
70 _ 1.9 years versus 61 + 1.4 years (p -- 0.03). A 
family history of arterial thrombotic events was 
elicited in 15 (75%) of 20 patients with APC 
resistance, similar to a rate of 129 of 153 patients 
without APC resistance (84%). A family history of  
venous thrombotic events was significantly more 
common in individuals with APC resistance-seven 
patients (35%) verses 12 patients (8%), respectively 
(p = 0.002). 
There were significant differences in APC-RR 
between subgroups of patients with peripheral vas- 
cular disease. The subgroup with the most abnormal 
APC-RR comprised those individuals with lower 
extremity occlusive disease (Table II), averaging 
2.22 -+ 0.03 (p < 0.001 vs control subjects). The 
subgroup of patients with aortic aneurysms also had 
APC-RR significantly lower than control subjects 
(p = 0.05) and not significantly different from 
patients with lower extremity occlusive c{isease. By 
contrast he mean APC-RR in the subgroup of 
patients with venous thrombosis (2.31 + 0.10) was 
not significantly different from that of the control 
subjects, but the statistical power of this observation 
was low as a result of the small number of individuals 
in this subgroup. Patients with carotid artery disease 
had APC-RR that appeared lower than normal 
(2.30 _+ 0.03), but this difference did not attain 
statistical significance (p = 0.07). 
The frequency of APC resistance was highest in 
the subgroup of patients with lower extremity 
occlusive disease; 13 (14%) of 95 patients had 
abnormal APC-RR. Patients with aortic aneurysms 
had APC resistance in three (12%) of 26 cases 
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Table I. Demographics of study patients 
APC Resistant Non Resistant p 
Patients 20 153 
Age* 68 + 1.9 60 + 1.4 0.04 
Sex (M/F) 13:7 107:46 NS1- 
Medical history 
Hypertension 4 (20%) 64 (42%) NSt 
Diabetes mellitus 2 (10%) 39 (25%) NS1- 
Coronary artery disease 9 (45%) 73 (48%) NS1- 
Hyperlipidemia 2 (10%) 23 (15%) NSt 
Malignancy 5 (25%) 21 (14%) NSt 
History of smoking 15 (75%) 133 (87%) NSt 
Family history 
Arterial events 15 (75%) 129 (84%) NSt 
Venous events 7 (35%) 12 (8%) 0.002 
NS, Not statistically significant; M/F, male/female. 
*Age at onset of symptoms. 
1-p > 0.05. 
Table II. APC resistance in control subjects and patients with peripheral vascular disease 
Group No. APC-RR ~ p? APC resistanceS: 
Control subjects 23 2.40 _+ 0.04 - 0 
Carotid artery disease 61 2.30 + 0.03 0.07 3 (4.9%) 
Aneurysm disease 26 2.26 + 0.06 0.05 3 (11.5%) 
Lower extremity occlusive disease 95 2.22 + 0.03 < 0.001 13 (13.7%) 
Venous thrombotic disease 11 2.31 + 0.10 > 0.10 1 (9.1%) 
~The ratio of the aPTI" with versus without he addition of exogenous APC. 
tTwo-tailed t test, compared with control group. 
~The number of individuals with APC-RR < 2.0. 
compared with one (9%) of 11 of patients with deep 
venous thrombosis. Patients with carotid artery 
disease had APC resistance in three (5%) of 61 cases, 
not siguificantly different from what would be 
predicted in the general population. 
Patients with abnormal APC-RR who underwent 
infrainguinal arterial reconstruction manifested sig- 
nificantly lower patency rates when compared with 
the subgroup of patients with normal APC-RR 
(Table III). Retrospectively, the patency of primary 
infrainguinal grafts placed in the patients with APC 
resistance was 48%_ 12% at 12 months and 
33% _ 18% at 5 years. These results were signifi- 
candy different from those observed in the patients 
without APC resistance, with corresponding patency 
rates of 88% -+ 8% at 12 months and 71% - 13% 
at 5 years (p = 0.04, Kaplan-Meier method, Peto- 
Prentice statistic). These differences could not be 
explained by differences in the frequency of patients 
with poor outflow or history of smoking. There were 
no such observed relationships in patients undergo- 
ing carotid endarterectomy or aortic aneurysm repair, 
but the numbers of patients were small enough to 
preclude meaningful conclusions. Patients with APC 
resistance and failed infrainguinal reconstructions 
rarely manifested a causative anatomic lesion at the 
time of operative revision or thrombolytic therapy 
(one of five patients, 20%), in contradistinction to a 
high frequency of explanatory lesions in patients with 
a normal APC response (15 of 19 patients, 79%, 
p = O.O2). 
DISCUSSION 
Protein C is a vitamin K--dependent plasma 
protein that may be activated uring thrombogenesis 
by forming a complex with thrombin and thrombo- 
modulin on the surface of endothelial cells. 1,2,12 APC 
and its cofactor, protein S, represent important 
components of the coagulation cascade, limiting 
ongoing thrombogenesis by binding to activated 
factors V and VIII. Endogenous APC-acts as an 
effective anticoagulant, and the agent has been used 
as an alternative to heparin. 13 
Hereditary resistance to APC was first described 
by Dahlb~ick in 19934 and was further characterized 
as an autosomal dominant alteration in factor V that 
prevents the normal APC-factor V anticoagulant 
mechanism. 7,14 It has been estimated that up to 90% 
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Table III. Retrospective analysis of infrainguinal grafts placed in patients with and without 
APC resistance 
APC-RR >-2.0 APC-RR <2.0 p 
Patients 66/76 (87%) 10/76 (13%) 
Graft type 
Autogenous 51/66 (77%) 8/10 (80%) NS ~ 
Nonautogenous 15/66 (23%) 2/10 (20%) NS * 
Mean follow-up 46 months 50 months NS ~ 
Patency rate~" 0.04 
12 months 88% -+ 8% 48% -+ 12% 
60 months 71% + 13% 33% + 18% 
Explanatory lesions$ 15/19 (79%) 1/5 (20%) 0.02 
NS, Not statistically significant. 
~p > 0.05. 
~Patency rates were calculated with Kaplan-Meier method and compared by use of the Peto-Prentice statistic. 
SExplanatory lesions were tabulated as the number of patients with anatomic lesions in the graft or inflow or outflow vessels that were 
detected at reoperation or after thrombolysis of the failed bypass graft. 
of cases with APC resistance can be explained by a 
mutation in the factor V gene, with a G to A 
transition at position 1691. 8 The defect occurs at a 
CpG dinucleotide, a recognized hot spot for muta- 
tion in the human genome. The G to A transition 
results in an Arg to Gin substitution at factor V heavy 
chain position 506, preventing inactivation of factor 
Va by APC as a result of the loss of a positive charge 
at the cleavage site. 15 
Individuals with APC resistance have been shown 
to be at substantial risk for venous thromboembolic 
events. 9,16 Similarly, young individuals with venous 
thrombosis have a high prevalence of APC resistance, 
approaching 40% in one series. 5 To date, the 
prevalence of APC resistance has not been thor- 
oughly investigated in the wide variety of peripheral 
vascular disorders exclusive of deep venous throm- 
bosis. Linblad et al.17 anecdotally documented three 
patients with peripheral arterial disease and APC 
resistance. Halbmayer et al. t8 documented APC 
resistance in 17% of 30 patients with juvenile or 
recurrent.stroke. In contrast o these studies, Cush- 
man et al.14 measured the APC-RR in 44 young 
patients with premature arterial disease and found 
only two (4.5%) with abnormal APC-RR. By 
comparison, the same investigators documented an 
abnormal APC-RR in nine (24%) of 37 patients with 
venous thrombotic disorders. 
This study was undertaken todefine the frequency 
and implications of APC resistance in patients with 
peripheral vascular disorders, both before and after 
operative intervention. We found a relatively high 
incidence of APC resistance in individuals with lower 
extremity occlusive disease and abdominal aortic 
aneurysms. Patients with carotid artery stenosis did 
not manifest an increased prevalence of the disorder. 
The explanation for the differing prevalence of APC 
resistance within different subcategories of vascular 
disease remains unexplained but may relate to the 
pathophysiology of symptoms within different com- 
ponents of the vascular tree. Disorders that are more 
dependent on platelet-mediated phenomena, such as 
carotid embolic events, would not be expected to be 
increased in patients with the coagulation disorder 
associated with APC resistance. By contrast, disor- 
ders intimately related to coagulation abnormalities, 
such as venous thrombosis, would be expected to be 
common in patients with APC resistance. 
We documented a family history of venous 
thrombotic events in a significant proportion of 
patients with APC resistance, consistent with the 
observations ofprevious investigators. 5,8By contrast, 
a family history of arterial disease was present at a 
similar rate in patients with and without APC 
resistance. These observations uggest that APC 
resistance, the same as other hypercoagulable phe- 
nomena, 12 may be associated with venous throm- 
botic events more frequently than arterial events. 
This hypothesis could not be directly tested in this 
series because of the nature of the population studied, 
a population selected on the basis of a high frequency 
of arterial disease. 
The most striking findings were observed in the 
subgroup of patients with APC resistance who 
underwent infrainguinal arterial bypass. Bypass graft 
thrombosis developed in a significant proportion of 
the patients, frequently within the first postoperative 
year. The patency rate of lower extremity reconstruc- 
tions in patients with APC resistance was substan- 
tially below that of patients with a normal APC 
response. Interestingly, patients with APC resistance 
and failed infrainguinal bypass grafts rarely displayed 
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an anatomic lesion explaining the occlusion. By 
contrast, the vast majority of patients without APC 
resistance who had thrombosis of an infrainguinal 
graft manifested a lesion that explained the failure. 
This observation suggests that the balance between 
mural thrombus deposition and dissolution is dis- 
turbed within the bypass grafts of patients with APC 
resistance such that thrombogenesis proceeds un- 
checked and graft failure ensues. 
Patients with APC resistance who had devel- 
opment of arterial disease tended to do so at an 
older age than those without the syndrome. This 
seemingly paradoxical observation is in keeping with 
the concept that APC resistance is not a risk factor 
for atherosclerosis itself; rather, the entity predis- 
poses to thrombosis over areas of preexistent en- 
dothelial compromise. Patients with APC resistance 
and arterial occlusions may represent individuals 
without accelerated atherosclerotic arterial disease. 
These individuals have age-dependent atheroscle- 
rotic change and develop thrombosis at the site of 
minor arterial lesions in association with their hy- 
percoagulability. Patients with APC resistance do 
not have development of thrombotic events early in 
life because they lack the precursor of an atherogenic 
focus, an inciting parameter that does not develop 
until an advanced age. This observed age relation- 
ship parallels the observations of Cushman et al., ~4 
who observed a low incidence of APC resistance in 
a group of young patients with accelerated ath- 
erosclerosis. 
In summary, APC resistance appears to represent 
a hypercoagulable state associated with an increased 
risk of arterial thrombotic events in addition to the 
well-described association with venous thromboem- 
boli. APC resistance is most prevalent in patients with 
symptomatic infrainguinal occlusive disease. Symp- 
tomatic peripheral disease tends to occur later in life 
in patients with APC resistance. Patients with APC 
resistance undergoing lower extremity bypass may be 
at an extraordinarily high risk of graft failure, and 
antithrombotic therapy is appropriate when revascu- 
larization becomes necessary. The preoperative iden- 
tification of APC resistance provides the opportunity 
to restore the normal balance of thrombosis and 
improve the long-term prospects for vascular recon- 
struction. An aggressive approach to the diagnosis 
and treatment of APC resistance and other hyperco- 
agulable syndromes is a prerequisite to accomplish 
satisfactory long-term patient outcome. With the lack 
of objective data on which to base therapy, we 
presently monitor symptom-free patients with APC 
resistance without anticoagulation but treat patients 
with symptoms and those who have undergone 
peripheral vascular procedures with long-term war- 
farin therapy. 
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DISCUSSION 
Dr. Thomas W. Wakefield (Ann Arbor, Mich.). This 
importa~at s udy examines the incidence of resistance to 
APC as a cause of hypercoagulability in patients undergo- 
ing vascular surgery with unexplained thrombosis. APC 
resistance was defined by a functional test, the APC index, 
a ratio of activated partial thromboplastin time with and 
without he addition of exogenous APC. This factor, which 
is a mutation in the gene encoding for factor V, has been 
recently suggested to be important as a marker for venous 
thrombosis, but as of yet few cases of arterial thrombosis 
with this defect have been reported. 
In this study a significant number of patients with 
peripheral vascular occlusive disease were noted to have 
APC resistance, and of those patients undergoing arterial 
reconstruction, occlusion was noted in 60% of patients 
with APC resistance. 
Additionally, the long-term patency rate at 5 years was 
significantly lower in patients with APC resistance as 
compared with those without this abnormality. The 
authors have brought o our attention an important marker 
that may help define those patients at risk for postoperative 
thrombosis. 
First, the authors found only a 9.1% incidence of APC 
resistance in patients with venous thrombotic disease. 
Others, as mentioned, have found a much higher incidence, 
approximately 20% to 40%, for APC resistance in these 
patients. Although I suspect this is due to the small number 
of patients with venous thrombotic disease in this study, 
can the authors speculate why they found such a low 
incidence in their patients with venous thrombosis? 
Although the difference in APC index between patients 
with failed versus patent reconstructions was statistically 
significant, he absolute values of the ratios were relatively 
close, 2.11 versus 2.26. In fact, the ratio of 2.11 is above 
the lower limit of normal in your laboratory as reported at 
2.0, and I believe that a patient with such a ratio would not 
be considered to have APC resistance. In view of this, do 
you believe that this test has great enough sensitivity that 
it can be used to predict those patients who will have 
thrombosis of their reconstructions, or can it only be used 
to categorize patients into a positive or negative category 
for APC resistance? Also, have you used any other 
techniques to assess directly for the presence or absence of 
the point mutation in the gene? 
Do you believe that we should be performing this test 
on all patients undergoing peripheral vascular surgical 
reconstructive procedures, or should we be screening 
specific subgroups of patients? If so, could you identify 
which subgroups hould be screened? 
Dr. Kenneth Ouriel. The first question relates to the 
low incidence of APC resistance in our group of patients 
with venous disease. Unfortunately, we only had 11 
patients in this group, so if we had two instead of one of 
11 with APC resistance, our rate of APC resistance would 
be closer to what others have found. If we need a number 
for venous disease, it's probably in excess of 20%. 
Second, I believe that the APC resistance test that we 
are using now, although very easy to perform and also very 
specific, is not as sensitive as it should be. Certainly patients 
with APC resistance ratios of 2.1 or 2.2 may have PCA 
resistance. In fact a better test for APC resistance is DNA 
analyses, which we have not yet done. When you do this 
you find a substantial number of patients who have APC 
resistance whose ratios are greater than 2. 
Do I believe that this test should be performed on all 
patients with peripheral vascular disease? The test is not yet 
clinically approved, but I believe it will be very shortly. It's 
an easy test to do, and I think that it certainly is reasonable. 
If we're going to get a PTr  on a patient, why not get a PTT 
with and without the addition of APC. So in the future, 
given the incidence of possibly 10% or 15% in the arterial 
population, in the future we will be doing this test, and we 
may even be doing DNA screening clinically in the not too 
distant future. 
Dr. Bengt Lindblat (Malm6, Sweden). Blood coagu- 
lation is down-regulated by the protein C anticoagulant 
system, and this activation is localized irectly to the vessel 
or to the endothelial cells by complex formation of 
thrombin to thrombomodulin and protein C. Protein S 
acts as a cofactor, and, as was recently found in our hospital, 
inactivated factor V acts as another cofactor that results in 
APC resistance. 
This APC resistance is thus due to a single point 
mutation in the factor V gene, which means that APC 
resistance can occur as heterozygous or homozygous 
mutation. At our hospital we have been caJculating that 
heterozygosity results in a tenfold risk for thromboembo- 
lism, but homozygosity increases that to about 100-fold. 
Myocardial infarction does not seem to be strongly 
correlated with APC resistance; however, does your group 
have any additional information concerning APC resistance 
in acute arterial extremity ischemia? 
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We have reported on a high incidence of APC 
resistance in patients with graft occlusion, especially early 
ones. Presently we are screening and treating patients with 
heterozygosity with increased anticoagulation during op- 
eration and homozygosity with a more optimal preopera- 
tive, intraoperative, and postoperative anticoagulation. 
How do yon treat patients with APC resistance before, 
during, and after vascular surgery? 
Dr. Ouriel. Because this series was primarily done in 
an outpatient setting, there were very few patients with 
acute limb ischemia, so I don't have data in that regard, but 
I believe that the APC resistance rate would be higher, 
certainly ifwe're looking at the usual population with acute 
ischemia which may be more than one half of individuals 
with graft thromboses. 
The second question had to do with how we treat 
patients with known APC resistance. At this time we have 
not been giving anticoagulants to those patients who are 
symptom free and who have APC resistance. But for 
patients who have had, for instance, a graft thrombosis in 
the past, we prescribe long-term oral anticoagulation. I  
the perioperative period we are aggressive with adminis- 
tration of heparin. 
Dr. David L. Gillespie (Potomac, Md.). Did you test 
whether your patients with resistance to APC also had the 
factor V DNA point mutation? As you know, this point 
mutation is believed to be responsible for this phenomenon 
in as many as 90% of patients tudied by Dahlb~ick et al. s 
A retrospective analysis of plasma samples in our laboratory 
has revealed it to be present in only 60% of patients 
admitted with venous thrombosis. In addition, most of the 
patients with APC resistance in our study are much 
younger than yours. We found this to be especially true in 
women admitted with venous thrombosis while using oral 
contraceptives. In addition, it has been reported that as 
many as 75% of these patients will have recurrence of 
venous thromboembolism. Because of their extremely high 
risk for venous thromboembolism, we recommend use of 
the Coatest assay to evaluate these patients for APC 
resistance. 
To date, three studies have been published stating that 
APC resistance is not a risk factor for stroke or myocardial 
infarction: one from Brigham and Women's Hospital, one 
from Helsinki, and one from Leeds. Why do you believe 
that APC resistance is a significant risk factor for lower 
extremity arterial occlusive disease? 
Dr. Ouriel. In terms of the DNA analyses, certainly 
that is a more accurate way to go. And whether it has a low 
sensitivity and high specificity, or the reverse, at present 
remains undefined. 
You talked about venous thrombosis occurring in 
younger patients. Atherosclerosis it elf is not accelerated by
APC resistance, but maybe a patient who has an athero- 
sclerotic lesion would be more likely to have thrombosis 
than if they had APC resistance. The incidence of patients 
with atherosclerotic stenoses increases with age, and maybe 
that's why we see more symptomatic disease in the elder 
patients with APC resistance. 
In terms of the Coatest, we should use this for clinical 
and experimental purposes only. 
Dr. Keith D. Calligaro (Philadelphia, Pa.). Patients 
with protein C deficiency, if you treat hem with warfarin 
(Coumadin), can get Coumadin-induced skin necrosis. 
Does the same hold true for patients with APC deficiency? 
Dr. Ouriel. I don't know. I can tell you that we have 
not seen that. We don't have a large number of patients 
with APC resistance receiving Coumadin, but we haven't 
seen that problem. 
Mr. John H.  N. Wolfe (London, United Kingdom). 
There have been data showing thrombosis related to 
fibrinogen levels and lipoprotein(a) levels. We were able to 
extrapolate from the thrombosis to show that those were 
also related to graft stenosis. In all these grafts there was no 
evidence of a localized lesion and yet you were following up 
these grafts for a long time in some cases before they 
thrombosed. I mean they formed different categories. If
there's avery early thrombosis, it might be clot formation; 
but at a later stage usually there's a lesion within the graft, 
as well as other problems. 
Dr. Ouriel. The bypass grafts that thrombosed in 
patients with APC resistance have lesions in a small 
percentage of cases. In our series it was one of six. But 
what's more interesting is that the grafts that thrombose do 
so early on. And if you look at life-table curves, you see that 
the fall-offis very early, and so these grafts are thrombosing 
early on, presumably because of an abnormal balance at the 
blood intimal junction of the graft. 
I should mention that the risk of problems of APC 
resistance in the lower extremity group was fairly high. In 
contrast o that, we found the incidence to be low in 
patients with carotid artery disease. And this may actually 
go along with some of the recent reports that stroke may 
not be associated with APC resistance. 
Dr. Mac Dryjski (Buffalo, N.Y.). Do you have any 
data regarding the incidence of coronary artery disease in 
your patients with APC resistance? Have you seen in- 
creased incidence of perioperative morbidity and mortality 
rates in this group of patients? 
Dr. Ouriel. We did examine that. We had the same 
incidence of coronary artery disease in the two groups. The 
numbers are too small to give you any conclusions in terms 
of perioperative mortality rates with regard to heart-related 
complications. 
